Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective Multicentre Cohort Study of the Prevalence and Clinical Impact of Germline Deleterious Mutations in DNA Repair Genes of Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Trial Profile

Prospective Multicentre Cohort Study of the Prevalence and Clinical Impact of Germline Deleterious Mutations in DNA Repair Genes of Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 04 Jun 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abiraterone (Primary) ; Cabazitaxel (Primary) ; Docetaxel (Primary) ; Enzalutamide (Primary) ; Radium 223 chloride (Primary)
  • Indications Prostate cancer
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms PROREPAIR-B
  • Most Recent Events

    • 04 Jun 2019 Results assessing pattern of disease progression (PSA, radiographic, clinical) in docetaxel versus Abiraterone + enzalutamide treated patients presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
    • 16 Feb 2019 Results analysing association of time to PSA progression and radiographic progression-free survival with overall survival, presented at the 2019 Genitourinary Cancers Symposium.
    • 01 Feb 2019 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top